Cargando…

Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients

Fanhdi/Alphanate is a plasma derived factor VIII concentrate used for treating hemophilia A, for which there has not been any dedicated model describing its pharmacokinetics (PK). A population PK model was developed using data extracted from the Web-Accessible Population Pharmacokinetic Service-Hemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chelle, Pierre, Yeung, Cindy H. T., Bonanad, Santiago, Morales Muñoz, Juan Cristóbal, Ozelo, Margareth C., Megías Vericat, Juan Eduardo, Iorio, Alfonso, Spears, Jeffrey, Mir, Roser, Edginton, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820598/ https://www.ncbi.nlm.nih.gov/pubmed/31115857 http://dx.doi.org/10.1007/s10928-019-09637-4

Ejemplares similares

Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
por: Chelle, Pierre, et al.
Publicado: (2019)

External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data
por: Chelle, Pierre, et al.
Publicado: (2021)

Impact of novel hemophilia therapies around the world
por: Ozelo, Margareth C., et al.
Publicado: (2022)

Focusing in on use of pharmacokinetic profiles in routine hemophilia care
por: Croteau, Stacy E., et al.
Publicado: (2018)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
por: McEneny-King, Alanna, et al.
Publicado: (2017)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
por: Yu, Jacky K., et al.
Publicado: (2019)

Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)
por: McEneny-King, Alanna, et al.
Publicado: (2016)

Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
por: Versloot, Olav, et al.
Publicado: (2022)

Immunogenicity of Current and New Therapies for Hemophilia A
por: Prezotti, Alessandra N. L., et al.
Publicado: (2022)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol
por: Iorio, Alfonso, et al.
Publicado: (2016)

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
por: Iorio, Alfonso, et al.
Publicado: (2018)

Clinical Efficacy and Safety of Fanhdi(®), a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study
por: Jiménez-Yuste, Víctor, et al.
Publicado: (2022)

两种重组人凝血因子Ⅷ制剂在血友病A患者中的群体药代动力学研究
por: Chelle, Pierre, et al.
Publicado: (2019)

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2018)

IDH1-mutated relapsed or refractory AML: current challenges and future prospects
por: Megías-Vericat, Juan Eduardo, et al.
Publicado: (2019)

Quantifying breast milk intake by term and preterm infants for input into paediatric physiologically based pharmacokinetic models
por: Yeung, Cindy H.T., et al.
Publicado: (2020)

Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics
por: Zhou, Jenny Y., et al.
Publicado: (2019)

Verifying in vitro‐determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically‐based pharmacokinetic modeling
por: Yeung, Cindy H. T., et al.
Publicado: (2023)

Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
por: De Padua, Valeria, et al.
Publicado: (2020)

Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation
por: Aborig, Mohamed, et al.
Publicado: (2019)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

HemoKinect: A Microsoft Kinect V2 Based Exergaming Software to Supervise Physical Exercise of Patients with Hemophilia
por: Mateo, Fernando, et al.
Publicado: (2018)

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
por: Megías-Vericat, Juan Eduardo, et al.
Publicado: (2022)

Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice
por: Pezeshkpoor, Behnaz, et al.
Publicado: (2022)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

Costs of the management of hemophilia A with inhibitors in Spain
por: Bonanad, Santiago, et al.
Publicado: (2021)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
por: Preijers, Tim, et al.
Publicado: (2020)

Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries
por: Usuba, Koyo, et al.
Publicado: (2019)

Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database
por: Versloot, Olav, et al.
Publicado: (2021)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients
por: Malik, Paul R. V., et al.
Publicado: (2019)

Addressing maternal medication use during breastfeeding using clinical resources and a novel physiologically based pharmacokinetic model-derived metric: A qualitative study
por: Yeung, Cindy Hoi Ting, et al.
Publicado: (2023)

Using Physiologically Based Pharmacokinetic Modeling for Mechanistic Insight: Cases of Reverse Translation
por: Edginton, Andrea N.
Publicado: (2017)

Efficacy and safety evaluation of Fanhdi(®), a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study
por: Jimenez‐Yuste, Victor, et al.
Publicado: (2021)

The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients
por: Núñez, Ramiro, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development
por: Maharaj, A R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ltna0dq7lqo4ctgrngddi97hbs